SCHEMBL31412944

SCHEMBL31412944

COc1cc2nccc(Oc3ccc(N(C(=O)C4(C(N)=O)CC4)c4ccc(F)cc4)cc3F)c2cc1OC

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 15/20 0.62
AXL P30530 8/20 0.62
KDR P35968 5/20 0.62
MERTK Q12866 3/20 0.55
RET P07949 3/20 0.54
KIT P10721 3/20 0.54
FLT3 P36888 3/20 0.54
AURKA O14965 2/20 0.54
RIPK2 O43353 2/20 0.54
ABL1 P00519 2/20 0.54
EGFR P00533 2/20 0.54
ERBB2 P04626 2/20 0.54
NTRK1 P04629 2/20 0.54
LCK P06239 2/20 0.54
LYN P07948 2/20 0.54
HCK P08631 2/20 0.54
ADRA2A P08913 2/20 0.54
BCR P11274 2/20 0.54
FGFR1 P11362 2/20 0.54
SRC P12931 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL408158 1.00 MET (0.62) METAXLKDRMERTKRET
SCHEMBL31412923 0.95 MET (0.57) METAXLKDRMERTKRET
SCHEMBL28676846 0.94 MET (0.57) METAXLKDRMERTKRET
SCHEMBL372297 0.94 AXL (0.55) METAXLKDRMERTKRET
SCHEMBL31412940 0.94 AXL (0.55) METAXLKDRMERTKRET
SCHEMBL374207 0.94 AXL (0.55) METAXLKDRMERTKRET
Hydrochloric Acid SCHEMBL15917992 0.93 MET (0.56) METAXLKDRMERTKRET
Hydrochloric Acid SCHEMBL15917934 0.93 MET (0.56) METAXLKDRMERTKRET
SCHEMBL3699549 0.93 MET (0.55) METAXLKDRMERTKRET
SCHEMBL3675221 0.93 MET (0.55) METAXLKDRMERTKRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119841776-A Tyrosine kinase inhibitors and uses thereof 华上生技医药股份有限公司 2025-04-18 CN disclosed
US-20250120967-A1 TYROSINE KINASES INHIBITORS AND USES THEREOF Great Novel Therapeutics Biotech & Medicals Corporation (TW) 2025-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250120967-A1 TYROSINE KINASES INHIBITORS AND USES THEREOF LCK, LTK, HIF1AN MET 592/4885AXL 339/4885KDR 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.